Skip to content
    ALC
    Earnings call· Jun 2025(Q2 FY25)

    ALCON INC ALC

    Aug 20, 2025 Source

    Executive summary

    Alcon Q2 FY25 — Strategic Acquisitions and New Product Launches Drive Future Growth Amidst Soft Surgical Market

    Alcon navigated a softer surgical market in Q2 FY25, particularly impacting revenue, leading to a revised full-year sales outlook. Despite near-term headwinds, the company made significant strategic moves with the acquisitions of STAAR Surgical and LumiThera, alongside successful launches of key products like Unity VCS, PanOptix Pro, and Tryptyr, positioning it for accelerated growth in the second half and beyond. Management remains confident in long-term market fundamentals and operational leverage.

    Highlights

    5

    • Acquisition of STAAR Surgical for $1.5 billion, expected to be accretive to earnings in year 2.

    • Acquisition of LumiThera's Valeda system, with estimated peak recurring revenue of $100 million to $150 million by 2030.

    • Strong initial demand for Unity VCS, with over 1,000 qualified leads in 10 weeks since its May launch.

    • PanOptix Pro helped stabilize U.S. premium IOL share with a modest sequential improvement of approximately 4 share points in Q2.

    • Tryptyr, a new dry eye treatment, launched in late July with estimated peak sales of $250 million to $400 million.

    Concerns

    5

    • Second quarter results fell short of expectations due to softer markets, primarily in Surgical.

    • Global cataract volumes grew approximately low single digits in Q2 and H1, compared to a historical average of 4%.

    • Full-year revenue guidance updated to $10.3 billion to $10.4 billion, reflecting soft surgical market and FX moves.

    • Full-year core operating margin guidance updated to 19.5% to 20.5% due to revised sales outlook.

    • Incurred $27 million in tariff-related charges in Q2, with full-year impact expected to be $100 million, an incremental $20 million headwind.

    Guidance & targets

    12
    CategoryTargetConfidence
    Full-year revenue
    $10.3 billion to $10.4 billion
    high materiality
    High
    Full-year sales growth rate (constant currency)
    between 4% and 5%
    high materiality
    High
    Full-year R&D as % of sales
    top half of our 8% to 10% of sales range
    medium materiality
    High
    Full-year core operating margin
    between 19.5% and 20.5%
    high materiality
    High
    Full-year nonoperating income and expense
    between $185 million and $205 million
    medium materiality
    High
    Full-year core average tax rate
    approximately 18%
    medium materiality
    High
    Full-year core diluted EPS
    between $3.05 to $3.15 per share
    high materiality
    High
    Full-year core diluted EPS year-over-year change (constant currency)
    between 0% and 2%
    high materiality
    High
    Valeda Light Delivery System peak recurring revenue
    $100 million to $150 million
    medium materiality
    Medium
    Tryptyr peak sales
    approximately $250 million to $400 million
    medium materiality
    Medium
    STAAR Surgical merger accretion
    accretive to earnings in year 2
    high materiality
    High
    STAAR Surgical merger closing timeframe
    6 to 12 months
    high materiality
    High

    Segment performance

    7
    SegmentRevenueYoYQoQMargin
    Surgical
    Revenue growth expressed in constant currency. Reflects soft market conditions.
    		$1.5 billion1%——
    Surgical - Implantables
    Reflects soft market conditions and competitive pressures. Growth expressed in constant currency.
    		$456 million-2%——
    Surgical - Consumables
    Growth led by vitreoretinal and cataract consumables, as well as price increases, despite soft market conditions. Growth expressed in constant currency.
    		$777 million4%——
    Surgical - Equipment
    Declines in legacy surgical equipment partially offset by sales of Unity VCS and Voyager DSLT. Growth expressed in constant currency.
    		$222 milliondown slightly——
    Vision Care
    Revenue growth expressed in constant currency.
    		$1.1 billion5%——
    Vision Care - Contact Lens
    Primarily driven by product innovation and price increases. Growth expressed in constant currency.
    		$692 million7%——
    Vision Care - Ocular Health
    Growth led by eye drops portfolio, partially offset by declines in contact lens care and pressure from divestment to OcuMension in China. Growth expressed in constant currency.
    		$430 million2%——

    Operational metrics

    20
    Core gross margin
    62.2%broadly in line with prior year
    Q2 FY25
    Core operating margin
    19.1%down 100 basis points
    Q2 FY25

    Primarily due to increased investment in R&D.

    Interest expense
    $51 millionbroadly in line with last year
    Q2 FY25
    Other financial income and expense
    $4 million
    Q2 FY25

    Net benefit.

    Average core tax rate
    17.7%down from 21.2% in prior year
    H1 FY25

    Due to discrete tax benefits in the current year compared to discrete tax expenses in the prior year.

    Share repurchases
    $121 million
    Q2 FY25

    Part of $287 million returned to shareholders.

    Dividend payments
    $166 million
    Q2 FY25

    Part of $287 million returned to shareholders.

    Tariff-related charges
    $27 million
    Q2 FY25

    For product not yet sold.

    Operating leverage
    150 basis points
    FY25

    Roughly 150 basis points of operating leverage expected this year, offset by tariff pressure and Aurion pressure. Expected to continue 150-200 bps historically.

    PanOptix Pro light utilization
    94%
    Q2 FY25

    Highest among trifocal IOLs.

    PanOptix Pro light scatter reduction
    50%compared to its predecessor
    Q2 FY25
    Dry eye patients in U.S.
    over 35 million
    Current
    Dry eye patients treated with prescription product
    fewer than 10%
    Current

    Of over 35 million dry eye sufferers in the U.S.

    Tryptyr full reimbursement timeline
    18 months
    Future

    Expected timeline for full reimbursement.

    Constellation system age
    almost 17 years old
    Current
    Surgical market moving annual total (MAT)
    2%closer to 1% last quarter
    12 months

    Refers to surgical procedural growth.

    Contact lens market moving annual total (MAT)
    6%
    12 months

    Typically 5% to 7%.

    OTC eye drops market growth
    4% to 5%
    Typical
    Long-term EPS growth goal (CAGR)
    12% to 15%
    Long-term

    Reiterated goal from Capital Markets Day.

    Tariff pressure on operating margin (gross impact)
    50 basis points
    FY26

    Estimated gross impact assuming tariffs are not offset, as some Q2 tariffs will roll into FY26 balance sheet.

    Industry KPIs

    10
    MetricValueDetails
    Tariff impact$100 millionUSD
    Pricing realized priceprice increases
    New product launch rampstrong order book
    Procedure volume growthlow single digits%
    FCF conversion leverage guidance4% to 5%%
    Installed base system placements30,000consoles
    Segment franchise organic growth1%%
    Sales force commercial capacity buildhired a new sales force
    Indicated addressable patient populationnearly 200 millionpeople
    Pivotal trial clinical evidence milestonesstatistically significant improvements

    Product announcements

    4
    ProductTypeDetails
    Unity VCSlaunch
    PanOptix Prolaunch
    Precision7 sphere and toric lensesupdate
    Tryptyrlaunch

    Deals & partnerships

    3
    Voyager DirectIntegrated the Voyager Direct selective laser trabeculoplasty device into Alcon's portfolio.

    This first noncontact laser therapy offers a streamlined, patient-friendly alternative to traditional SLT and positions Alcon to accelerate global adoption of laser-first treatments for glaucoma.

    STAAR SurgicalDefinitive merger agreement to acquire STAAR Surgical and its market-leading EVO family of ICLs for vision correction.$1.5 billion

    The acquisition strengthens Alcon's offering by broadening solutions for high myopes, complementing existing laser vision correction platforms. It leverages Alcon's commercial infrastructure to accelerate EVO ICL adoption globally. Longer term, internal product development teams will explore combining IOL optical designs with the collamer platform to develop a presbyopia correcting ICL. The transaction is subject to customary closing conditions, including regulatory approvals and STAAR shareholder approval.

    LumiTheraAcquisition of LumiThera and its Valeda Light Delivery System.

    The Valeda system is the first FDA authorized medical device that uses photobiomodulation to stimulate the retina's natural ability to heal and regenerate, addressing early and intermediate dry age-related macular degeneration (AMD). It is a noninvasive in-office therapy shown to improve visual function and slow AMD progression. Alcon plans to pursue CMS reimbursement.

    Risks & headwinds

    6
    Softer Surgical MarketQ2 and H1 FY25

    Global cataract volumes grew approximately low single digits in Q2 and H1, compared to a historical average of 4%.

    Mitigation: Management expects a return to the historical average due to underlying market fundamentals (aging population, increasing cataract prevalence) and new product launches like Unity VCS and PanOptix Pro.

    Competitive Pressures in IOLsQ2 FY25

    Some share loss in international markets, particularly Europe, due to new competitor products.

    Mitigation: PanOptix Pro is helping stabilize U.S. premium IOL share. Alcon expects continued competitiveness in the IOL space for the next 18-24 months and plans to be active with its own product pipeline.

    Tariff ImpactQ2 FY25 and FY25

    $27 million in Q2 tariff-related charges ($12 million in COGS, $15 million on balance sheet); full-year impact expected to be $100 million (incremental $20 million vs. May forecast).

    Mitigation: Mitigation primarily through foreign exchange benefits (strong U.S. dollar) and operational actions. Evaluating manufacturing footprint changes for long-term stability, but larger moves await stable policy.

    Macroeconomic Headwinds in ChinaCurrent

    Affecting EVO revenue.

    Mitigation: Management remains confident in the long-term opportunity in China, expecting it to be the largest single eye care market. The STAAR acquisition is viewed as a long-term strategic move, leveraging Alcon's critical mass and comprehensive offering.

    Increased R&D InvestmentQ2 FY25

    Led to a 100 basis point decline in core operating margin in Q2.

    Mitigation: These investments are strategic, aimed at driving future innovation and growth, and are expected to contribute to strong operating leverage and significant free cash flow in the long term.

    OcuMension Divestment and Supply IssuesQ2 and Q3 FY25

    Pressure on Ocular Health sales, expected to continue through Q3.

    Mitigation: Underlying growth in Systane remains healthy, and the company is addressing supply issues.

    What to watch in Q3 FY25

    5

    Surgical market growth

    Next couple of quarters
    CurrentLow single digits (Q2 and H1 FY25)
    TargetReturn to historical average of ~4%

    Why it matters

    Underlying market growth is a key driver for Alcon's surgical segment performance and overall revenue, impacting the company's ability to achieve its long-term growth targets.

    We've had a number of really good years that were above 4% globally. And I think what you're seeing right now is just kind of a normalization that's happening. So look, we're going to give it a couple of quarters.

    Q&A highlights

    7

    Can you elaborate on the stabilization of U.S. PC-IOL share with PanOptix Pro and comment on AT-IOL share outside the U.S.?

    U.S. PC-IOL share improved sequentially by about 4 points in Q2, attributed to PanOptix Pro's reception and a competitive outage. International markets, particularly Europe, experienced pressure and some share loss due to new competitor products, with the IOL space expected to remain competitive globally for the next 18-24 months.

    “the second quarter for us was sequentially better by about 4 share points. It was -- I think, obviously, PanOptix Pro has been well received for all the reasons I mentioned in the remarks, and I'm pleased with the way it's performing right now.”

    asked by Jeff Johnson · answered by David Endicott

    2 min read5 chapters

    Detailed Narrative

    01

    Strategic Acquisitions Expand Market Presence

    Alcon announced the acquisition of STAAR Surgical for $1.5 billion, integrating its market-leading EVO family of ICLs to address high myopes and strengthen its refractive surgery offering. This move complements Alcon's existing laser platforms and is expected to be accretive to earnings in year 2 post-closing. Additionally, the company acquired LumiThera and its Valeda Light Delivery System, the first FDA-authorized medical device for early to intermediate dry age-related macular degeneration (AMD), a condition affecting nearly 200 million people globally. Valeda has estimated peak recurring revenue of $100 million to $150 million by 2030, contingent on reimbursement and penetration.

    02

    Innovation Drives Surgical Segment Performance

    The new Unity VCS, a combined vitreoretinal cataract system, launched in May and has garnered over 1,000 qualified leads in 10 weeks, with regulatory approvals in key markets. The launch is deliberate, focusing on comprehensive support for surgeons. In implantables, PanOptix Pro, an advancement in trifocal IOLs, delivers 94% light utilization and 50% reduced light scatter, contributing to a modest sequential improvement in U.S. premium IOL share in Q2. These innovations are critical for driving growth in the surgical segment.

    03

    Vision Care Bolstered by New Product Launches

    The contact lens portfolio continued solid performance, fueled by the advancement of Precision7 sphere and toric lenses in the U.S. These weekly replacement lenses, featuring a novel silicone hydrogel material and active flow system, are receiving strong practitioner feedback. In ocular health, the FDA approval and late July launch of Tryptyr, a first-in-class neuromodulator for dry eye disease, addresses a significant unmet need among over 35 million U.S. sufferers. Tryptyr has estimated peak sales of $250 million to $400 million, with full reimbursement expected in approximately 18 months.

    04

    Market Dynamics and Financial Outlook Adjustments

    Global cataract volumes grew approximately low single digits in Q2 and H1, below the historical average of 4%, leading to a revised full-year revenue guidance of $10.3 billion to $10.4 billion. This adjustment also reflects recent U.S. dollar movements. Despite the softer surgical market, the retail contact lens market grew mid-single digits. The company anticipates sales growth to accelerate in the second half, predominantly in Q4, driven by new product introductions. Full-year core operating margin guidance was updated to 19.5% to 20.5% due to the revised sales outlook, while core diluted EPS guidance was maintained at $3.05 to $3.15 per share.

    05

    Tariff Headwinds and Mitigation Efforts

    Alcon incurred $27 million in tariff-related charges during Q2, with $12 million recognized in cost of sales and $15 million recorded on the balance sheet. The full-year tariff impact🌐 is now expected to be approximately $100 million, representing an incremental headwind of $20 million compared to May's forecast. The company aims to fully offset this impact through a combination of foreign exchange benefits and operational actions, including evaluating manufacturing footprint adjustments, though larger moves await stable policy.

    AI-generated summary of the company’s earnings call. Not investment advice.